semaglutide patent date When do the patents on OZEMPIC expire, and when will generic OZEMPIC be available? Massive Rs 50,000 Cr Opportunity

Safety Advice & Lifestyle Management

Whatever you require, we offer a comprehensive service you can rely on

In most cases, adults may qualify for GLP-1 weight loss medications with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related health condition such as high blood pressure, type 2 diabetes, prediabetes, high cholesterol, sleep apnea, or cardiovascular disease

Abstract The STEP 5 trial assessed the efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg versus placebo (both plus behavioral intervention) for long-term treatment of adults with obesity, or overweight with at least one weight-related comorbidity, without diabetes